Physician profile
Amar S Naik
NPI 1457433955
$1,222,050.06
in general payments reported to CMS, 2019-2025
15 companies · $324K in 2025
The $324K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128K · 2020: $32K · 2021: $55K · 2022: $201K · 2023: $155K · 2024: $327K · 2025: $324K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $629K · Travel and Lodging: $115K · Consulting Fee: $44K · Food and Beverage: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $628,603.90 |
| Travel and Lodging | $115,134.78 |
| Consulting Fee | $44,175.88 |
| Food and Beverage | $17,723.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $324,093.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299,701.40 | 2019-2025 | Entyvio |
| Lilly USA, LLC | $208,629.74 | 2022-2025 | Omvoh, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $192,845.87 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $112,253.94 | 2020-2025 | Tremfya, Stelara |
| Pfizer INC. | $77,358.95 | 2019-2024 | |
| Celgene Corporation | $4,264.97 | 2021-2024 | Zeposia |
| Eli Lilly and Company | $1,443.12 | 2022-2025 | Omvoh |
| Cook Medical LLC | $614.97 | 2019-2025 | Hemospray, Echotip Insight, Fusion |
| Biogen, INC. | $300.00 | 2021-2025 | Tysabri |
| Janssen Scientific Affairs, LLC | $282.39 | 2019-2025 | Tremfya |
| Steris Corporation | $168.99 | 2024-2025 | |
| Madrigal Pharmaceuticals | $47.09 | 2025 | Rezdiffra |
| Ardelyx, INC. | $25.39 | 2023 | Ibsrela |
| Evoke Pharma, INC. | $19.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.